蛋白质组学国际实验室获得了最高一级认证,提高了其进行早期癌症和其他疾病的血液测试的能力。 Proteomics International Labs gained top-tier accreditation, boosting its ability to develop blood tests for early cancer and other diseases.

蛋白质组国际实验室获得了加利福尼亚州欧文实验室的CAP认证,这是一流的质量标准,超过了CLIA的要求. Proteomics International Laboratories has earned CAP accreditation for its Irvine, California, lab, a top-tier quality standard exceeding CLIA requirements. 认证是在严格审查记录、安全、工作人员和设备之后进行的。 The certification followed a rigorous review of records, safety, staff, and equipment. 实验室最近增加了一个最先进的质谱光谱仪平台,使其能力超过用于糖尿病肾病PromarkerD测试的现有免疫测定系统。 The lab recently added a state-of-the-art mass spectrometry platform, boosting capabilities beyond its current immuno-assay systems used for the PromarkerD test for diabetic kidney disease. 这一升级支持了2026年计划的商业发射PromarkerEso,这是在美国授予专利后对食道动物肾上腺癌进行血液测试,并将帮助开发其他精确诊断,如用于内分泌硬化的PromarkerEndo。 This upgrade supports the planned 2026 commercial launch of PromarkerEso, a blood test for esophageal adenocarcinoma, following a U.S. patent grant, and will aid development of other precision diagnostics like PromarkerEndo for endometriosis. 认证加强了Proteomics在推动早期疾病检测和改善患者结果方面的作用。 The accreditation strengthens Proteomics’ role in advancing early disease detection and improving patient outcomes.